| Income Statement | 2025-09-30 | 2025-06-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 1,752 | - | 1,141 | |
| Research and development | 11,149 | - | - | |
| General and administrative | 8,228 | - | 7,688 | |
| Research and development | - | - | 8,902 | |
| Total operating expenses | 19,377 | - | 16,590 | |
| Loss from operations | -17,625 | - | -15,449 | |
| Interest expense | 1,314 | - | - | |
| Interest income | 207 | - | - | |
| Other (expense) income, net | -1,319 | - | - | |
| Total other (expense) income | -2,426 | - | 169 | |
| Net loss | -20,051 | - | -15,280 | |
| Redeemed series b convertible preferred stock | - | - | -4,988 | |
| Net loss attributable to shareholders - basic-Common Stock | -20,051 | - | - | |
| Net loss available to common shareholders— basic | - | - | -10,292 | |
| Net loss attributable to shareholders - basic-Series BPreferred Stock | 0 | 0 | - | |
| Net loss available to common shareholders— diluted | - | - | -10,292 | |
| Net loss attributable to shareholders - diluted | -20,051 | - | - | |
| Basic eps | - | - | -0.04 | |
| Diluted eps | - | - | -0.04 | |
| Basic average shares | - | - | 257,353,857 | |
| Diluted average shares | - | - | 257,353,857 | |
| Net loss per share attributable to shareholders - basic (in usd per share) | - | 0 | - | |
| Net loss per share attributable to shareholders - diluted (in usd per share) | - | 0 | - | |
| Weighted shares used in calculating net loss per share - basic (in shares) | - | 0 | - | |
| Weighted shares used in calculating net loss per share - diluted (in shares) | - | 0 | - | |
| Net loss per share attributable to shareholders - basic (in usd per share) | -0.07 | - | - | |
| Net loss per share attributable to shareholders - diluted (in usd per share) | -0.07 | - | - | |
| Weighted shares used in calculating net loss per share - basic (in shares) | 304,003,247 | - | - | |
| Weighted shares used in calculating net loss per share - diluted (in shares) | 304,003,247 | - | - | |
Ocugen, Inc. (OCGN)
Ocugen, Inc. (OCGN)